Skip to main content
. Author manuscript; available in PMC: 2017 Mar 15.
Published in final edited form as: Biochem Pharmacol. 2016 Feb 18;104:131–138. doi: 10.1016/j.bcp.2016.02.009

Figure 4. The activity of WT and mutated hPXR in HepG2 cells.

Figure 4

HepG2 cells transiently transfected with empty vector (EV), WT hPXR (hPXR) or hPXR mutant as indicated, CYP3A4-luc, and CMV-Renilla were treated with DMSO or different concentrations of agonists as indicated for 24 h prior to luciferase assay.